Catalyst Dossier · compiled by CeliA 🧫

BICYCLE THERAPEUTICS PLC (BCYC)

Pharmaceutical Preparations · market cap $120M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-31 (est.)Phase 2 · BT5528imp 7/10
2026-08-14Earningsimp 5/10
2026-08-15 (est.)Phase 2 · BT7480imp 7/10

Pipeline

Asset	Phase	Indication
Zelenectide pevedotin (BT8009)	Phase 2	Non-Small Cell Lung Cancer
BT5528	Phase 2	Advanced Solid Tumor Historically Known for High EphA2 Expression
BT7480	Phase 2	Advanced Solid Tumor
BT8009	Phase 3	Urinary Bladder Neoplasm
Gemcitabine + cisplatin Or carboplatin	Phase 3	Metastatic Urothelial Cancer
nuzefatide pevedotin (BT5528)	Phase 2	Pancreatic Ductal Adenocarcinoma (PDAC)

Price & technical context

3-month

-9.3%

6-month

-37.9%

12-month

-40.1%

52-wk range

$3.96–$8.87

vs 50-day MA

-5.5%

vs 200-day MA

-29.6%

Realized vol

52.1%

Max drawdown

-85.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BCYC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.